Investor interest in artificial intelligence-powered drug discovery shows little signs of wearing off, as start-up Genesis Therapeutics rakes in an impressive $200 million
Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi
US medical device company HDL Therapeutics is aiming to list on the Nasdaq via a merger with Swiftmerge Acquisition, a special purpose acquisition company (SPAC).
Despite the economic downturn, UK life sciences companies raised a healthy £382 million ($486 million) in new financing in the second quarter of the year, with venture cap
In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill